Effects of Actissist, a digital health intervention for early psychosis
Randomised clinical trial published in Psychiatry Research 2024
Science led
We work with leading researchers and clinicians across extended timeframes to validate our products as safe, accessible and effective at improving outcomes for people living with and at risk of severe mental illness.
To date, five randomised controlled trials have validated the CareLoop platform.
User engagement for a digital health intervention for early psychosis (Actissist 2.0)
Randomised controlled trial published in Psychiatry Review 2023
Exploring engagement with the CBT-informed Actissist smartphone app for early psychosis
Research article published in the Journal of Mental Health 2023
Digital screening for postnatal depression: mixed methods proof-of-concept study
Randomised controlled trial published in BMC Pregnancy & Childbirth 2022
The EMPOWER blended digital intervention for relapse prevention in schizophrenia
Randomised controlled trial published in The Lancet Psychiatry 2022
Smartphone-Enhanced Symptom Management In Psychosis: Open, Randomized Controlled Trial
Peer reviewed clinical study published in the Journal of Medical Internet Research
Early signs monitoring to prevent relapse in psychosis and promote wellbeing, engagement, recovery
Peer reviewed international clinical study published in Journal of Medical Internet Research 2020
Developing a Theory-Informed Smartphone App for Early Psychosis
Clinical study published in Frontiers in Psychiatry 2020
Smartphone-enhanced symptom management in psychosis: An open, randomised controlled trial
Clinical trial registration with the National Institute of Health Research CRN portfolio 2019
A Randomised Controlled Trial Of Smartphone Active Symptom Monitoring In Psychosis
Clinical study published in The Journal of Psychosis and Related Disorders 2018
Assessing therapeutic alliance in the context of mHealth interventions for mental health problems
Peer reviewed study published in JMIR mHealth and uHealth 2014
The feasibility and validity of ambulatory self-report of psychotic symptoms using a smartphone software application
Research article published in Archives of Suicide Research 2013
Certified and approved
Recommended on the NICE Early Value Assessment, CareLoop is also DTAC-approved, ISO 13485 certified, and registered with the MHRA as a Class I medical device, ensuring compliance with the highest standards of clinical effectiveness, data security, and regulatory requirements for digital health technologies in the NHS.
Request a demo